{'fraction_non_alphanumeric': 0.02332979851537646, 'fraction_numerical': 0.006362672322375398, 'mean_word_length': 5.7913669064748206, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Single-Cell RNA Sequencing Could Improve Myeloma Treatment

ATLANTA—New research suggests relapsed myeloma patients may require highly individualized therapy to overcome the complexity of the disease during relapse. The data, which was presented at the 2017 American Society of Hematology Annual Meeting, found that single-cell RNA sequencing is an important tool that could improve characterization and treatment of these patients (Abstract 62). “Genomic variation within a cancer in an individual patient (clonal heterogeneity) contributes to chemotherapy resistance in cancer,” noted study author Samir Parekh, MBBS, Associate Professor of Oncological Sciences, Medicine, Hematology and Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “We have been studying genomic heterogeneity in myeloma at Mount Sinai to improve our understanding and treatment of relapsed myeloma patients in our clinic.”